DK2014678T3 - KDR-peptider og vacciner indeholdende disse - Google Patents

KDR-peptider og vacciner indeholdende disse

Info

Publication number: DK2014678T3
Authority: DK; Denmark
Prior art keywords: peptides; amino acid; vaccines containing; seq; acid sequence
Prior art date: 2002-09-12

Application number

DK08018875.8T

Other languages

English (en)

Inventor

Takuya Tsunoda

Hideaki Tahara

Satoshi Wada

Original Assignee

Oncotherapy Science Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-12

Filing date

2003-09-12

Publication date

2012-02-06

2003-09-12 Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc

2012-02-06 Application granted granted Critical

2012-02-06 Publication of DK2014678T3 publication Critical patent/DK2014678T3/da

Links

229960005486 vaccine Drugs 0.000 title abstract 2
102000004196 processed proteins & peptides Human genes 0.000 abstract 5
108090000765 processed proteins & peptides Proteins 0.000 abstract 5
125000003275 alpha amino acid group Chemical group 0.000 abstract 3
239000003814 drug Substances 0.000 abstract 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4203—Receptors for growth factors
- A61K40/4208—Vascular endothelial growth factor receptors [VEGFR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/50—Colon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Oncology (AREA)
Mycology (AREA)
Microbiology (AREA)
Zoology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Cell Biology (AREA)
Dermatology (AREA)
Hematology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)

DK08018875.8T 2002-09-12 2003-09-12 KDR-peptider og vacciner indeholdende disse DK2014678T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
JP2002267285		2002-09-12
JP2003062003		2003-03-07
JP2003167042		2003-06-11
EP03795432A EP1548032B9 (en)	2002-09-12	2003-09-12	Kdr peptides and vaccines comprising the same

Publications (1)

Publication Number	Publication Date
DK2014678T3 true DK2014678T3 (da)	2012-02-06

Family

ID=31998762

Family Applications (6)

Application Number	Title	Priority Date	Filing Date
DK08018875.8T DK2014678T3 (da)	2002-09-12	2003-09-12	KDR-peptider og vacciner indeholdende disse
DK10010175.7T DK2267023T3 (da)	2002-09-12	2003-09-12	KDR-peptider og vacciner omfattende det samme
DK10010174.0T DK2267022T3 (da)	2002-09-12	2003-09-12	KDR-peptider og vacciner omfattende det samme
DK10010173.2T DK2261249T3 (da)	2002-09-12	2003-09-12	KDR-peptider og vacciner omfattende det samme
DK10010169.0T DK2267021T3 (da)	2002-09-12	2003-09-12	KDR-peptider og vacciner omfattende det samme
DK03795432T DK1548032T3 (da)	2002-09-12	2003-09-12	KDR-peptider og vacciner indeholdende disse

Family Applications After (5)

Application Number	Title	Priority Date	Filing Date
DK10010175.7T DK2267023T3 (da)	2002-09-12	2003-09-12	KDR-peptider og vacciner omfattende det samme
DK10010174.0T DK2267022T3 (da)	2002-09-12	2003-09-12	KDR-peptider og vacciner omfattende det samme
DK10010173.2T DK2261249T3 (da)	2002-09-12	2003-09-12	KDR-peptider og vacciner omfattende det samme
DK10010169.0T DK2267021T3 (da)	2002-09-12	2003-09-12	KDR-peptider og vacciner omfattende det samme
DK03795432T DK1548032T3 (da)	2002-09-12	2003-09-12	KDR-peptider og vacciner indeholdende disse

Country Status (13)

Country	Link
US (5)	US7514084B2 (da)
EP (11)	EP2267023B1 (da)
JP (3)	JP3971769B2 (da)
CN (5)	CN101139393B (da)
AT (2)	ATE531729T1 (da)
AU (1)	AU2003264419A1 (da)
CY (2)	CY1109463T1 (da)
DE (1)	DE60327786D1 (da)
DK (6)	DK2014678T3 (da)
ES (2)	ES2375299T3 (da)
PT (2)	PT2014678E (da)
SI (2)	SI2014678T1 (da)
WO (1)	WO2004024766A1 (da)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2267023B1 (en) *	2002-09-12	2015-02-11	Oncotherapy Science, Inc.	KDR peptides and vaccines comprising the same
US9090673B2 (en)	2003-12-12	2015-07-28	City Of Hope	Synthetic conjugate of CpG DNA and T-help/CTL peptide
JP4628208B2 (ja) *	2004-08-10	2011-02-09	オンコセラピー・サイエンス株式会社	Ｃｘａｄｒｌ１またはｇｃｕｄ１タンパク質を発現する胃癌または結腸直腸癌の治療のためのペプチドワクチン
DK2325306T3 (da)	2005-02-25	2014-03-03	Oncotherapy Science Inc	Peptidvacciner mod lungecancere, som udtrykker TTK-, URLC10- eller KOC1-polypeptid
EP2289532A1 (en)	2005-02-28	2011-03-02	Oncotherapy Science, Inc.	Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
US20060234941A1 (en)	2005-04-15	2006-10-19	The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services	Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
WO2007013480A2 (en)	2005-07-29	2007-02-01	Oncotherapy Science, Inc.	Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
WO2007070660A2 (en)	2005-12-13	2007-06-21	President And Fellows Of Harvard College	Scaffolds for cell transplantation
WO2008017517A1 (en) *	2006-08-11	2008-02-14	Life Sciences Research Partners Vzw	Immunogenic peptides and their use in immune disorders
TWI441648B (zh) *	2007-01-03	2014-06-21	Oncotherapy Science Inc	Ｆｏｘｐ３胜肽疫苗
ES2405763T3 (es)	2007-02-16	2013-06-03	Oncotherapy Science, Inc.	Vacunoterapia para la neovascularización coroidea
TW201425333A (zh)	2007-04-11	2014-07-01	Oncotherapy Science Inc	腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
TW200908998A (en) *	2007-06-27	2009-03-01	Oncotherapy Science Inc	Compositions and methods of treating cancer
ES2537323T3 (es)	2007-08-20	2015-06-05	Oncotherapy Science, Inc.	Péptido CDCA1 y agente farmacéutico que lo comprende
KR101543624B1 (ko)	2007-08-20	2015-08-11	온코세라피 사이언스 가부시키가이샤	Ｆｏｘｍ１ 펩티드 및 이를 포함하는 약학적 조성물
TWI436775B (zh) *	2007-08-24	2014-05-11	Oncotherapy Science Inc	以抗原胜肽合併化療藥劑治療胰臟癌
TW200932260A (en) *	2007-11-28	2009-08-01	Oncotherapy Science Inc	STAT3 epitope peptides
CA2715460C (en)	2008-02-13	2020-02-18	President And Fellows Of Harvard College	Continuous cell programming devices
US20120009678A1 (en)	2008-02-14	2012-01-12	Jean-Marie Saint-Remy	Immunotherapy targeting intracellular pathogens
EP2245059B1 (en)	2008-02-14	2017-09-20	Life Sciences Research Partners VZW	Cd4+ t-cells with cytolytic properties
WO2009101205A2 (en)	2008-02-14	2009-08-20	Life Sciences Research Partners Vzw	Immunogenic control of tumours and tumour cells
WO2009101204A2 (en)	2008-02-14	2009-08-20	Life Sciences Research Partners Vzw	Elimination of immune responses to viral vectors
TW201000119A (en) *	2008-06-10	2010-01-01	Oncotherapy Science Inc	MYBL2 epitope peptides and vaccines containing the same
TWI526219B (zh)	2008-06-19	2016-03-21	腫瘤療法科學股份有限公司	Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
EP2350118B1 (en)	2008-09-19	2016-03-30	Nektar Therapeutics	Carbohydrate-based drug delivery polymers and conjugates thereof
MX2011004176A (es)	2008-10-22	2011-09-21	Oncotherapy Science Inc	Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo.
TWI539160B (zh) *	2008-12-05	2016-06-21	腫瘤療法科學股份有限公司	Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
TW201032820A (en) *	2008-12-16	2010-09-16	Oncotherapy Science Inc	ELOVL7 epitope peptides and vaccines containing the same
KR20110117112A (ko) *	2008-12-24	2011-10-26	온코세라피 사이언스 가부시키가이샤	Ｃ１ｏｒｆ５９ 펩티드 및 이를 포함하는 백신
CN103690928B (zh)	2009-01-08	2016-04-20	株式会社癌免疫研究所	新型癌抗原eEF2
KR20110134446A (ko) *	2009-03-04	2011-12-14	온코세라피 사이언스 가부시키가이샤	Ｖａｎｇｌ１ 펩티드 및 이를 포함한 백신
KR101744514B1 (ko) *	2009-03-18	2017-06-08	온코세라피 사이언스 가부시키가이샤	Ｎｅｉｌ3 펩티드 및 이를 포함하는 백신
TW201100090A (en) *	2009-04-01	2011-01-01	Oncotherapy Science Inc	C6orf167 peptides and vaccines containing the same
TWI507204B (zh) *	2009-05-26	2015-11-11	Oncotherapy Science Inc	Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗
TW201109029A (en) *	2009-06-11	2011-03-16	Oncotherapy Science Inc	Vaccine therapy for choroidal neovascularization
AU2010278702C1 (en) *	2009-07-31	2016-07-14	Forsyth Dental Infirmary For Children	Programming of cells for tolerogenic therapies
TW201200525A (en) *	2009-12-04	2012-01-01	Oncotherapy Science Inc	MYBL2 peptides and vaccines containing the same
TW201136604A (en)	2009-12-14	2011-11-01	Oncotherapy Science Inc	TMEM22 peptides and vaccines including the same
CN102115492B (zh) *	2010-01-05	2013-03-06	中国农业科学院北京畜牧兽医研究所	血管内皮生长因子受体部分多肽及其应用
US8933014B2 (en)	2010-03-11	2015-01-13	Oncotherapy Science, Inc.	HJURP peptides and vaccines including the same
TW201134480A (en) *	2010-04-08	2011-10-16	Oncotherapy Science Inc	CLUAP1 peptides and vaccines including the same
JP2013523084A (ja) *	2010-04-09	2013-06-17	オンコセラピー・サイエンス株式会社	Ｃｄｃａ５ペプチドおよびそれを含むワクチン
TW201211250A (en) *	2010-09-07	2012-03-16	Oncotherapy Science Inc	VANGL1 peptides and vaccines including the same
HRP20200310T1 (hr)	2010-10-06	2020-08-21	President And Fellows Of Harvard College	Hidrogelovi koji stvaraju pore pogodni za injekcije, namijenjeni staničnim terapijama na bazi materijala
US10023847B2 (en)	2010-11-25	2018-07-17	Imnate Sarl	Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
TWI618541B (zh)	2010-12-02	2018-03-21	腫瘤療法科學股份有限公司	Ｔｏｍｍ３４胜肽與含此胜肽之疫苗
US9675561B2 (en)	2011-04-28	2017-06-13	President And Fellows Of Harvard College	Injectable cryogel vaccine devices and methods of use thereof
GB201201511D0 (en)	2012-01-30	2012-03-14	Univ Leuven Kath	Modified epitopes for boosting CD4+ T-cell responses
KR20140138900A (ko)	2012-03-09	2014-12-04	온코세라피 사이언스 가부시키가이샤	펩티드를 포함한 의약 조성물
ES2773895T3 (es)	2012-04-16	2020-07-15	Harvard College	Composiciones de sílice mesoporosa para modular las respuestas inmunitarias
US9416189B2 (en)	2012-05-11	2016-08-16	Microbial Chemistry Research Foundation	Anti-CXADR antibody
EP2872532A4 (en)	2012-07-10	2016-04-13	Oncotherapy Science Inc	CDCA1-EPITOPPEPTIDES FOR TH1 CELLS AND VACCINES THEREWITH
WO2014087626A1 (en) *	2012-12-04	2014-06-12	Oncotherapy Science, Inc.	Sema5b peptides and vaccines containing the same
WO2014123227A1 (ja)	2013-02-08	2014-08-14	株式会社医学生物学研究所	ヒトｎｒｇ１タンパク質に対する抗体
GB201309469D0 (en)	2013-05-28	2013-07-10	Imcyse Sa	Detection of CD4+ T lymphocytes
JP2017042047A (ja) *	2013-12-06	2017-03-02	オンコセラピー・サイエンス株式会社	Ｖｅｇｆｒ２由来ペプチドおよびそれを含むワクチン
CN107073090A (zh)	2014-04-30	2017-08-18	哈佛学院董事会	结合的疫苗装置和杀死癌细胞的方法
GB201418433D0 (en)	2014-10-17	2014-12-03	Imcyse Sa	Novel immunogenic peptides
WO2016123573A1 (en)	2015-01-30	2016-08-04	President And Fellows Of Harvard College	Peritumoral and intratumoral materials for cancer therapy
WO2016129335A1 (ja) *	2015-02-09	2016-08-18	株式会社ライフアートビレッジ	免疫細胞療法のためのペプチドスクリーニング方法
US11150242B2 (en)	2015-04-10	2021-10-19	President And Fellows Of Harvard College	Immune cell trapping devices and methods for making and using the same
US10729791B2 (en)	2015-05-18	2020-08-04	Imcyse Sa	Animal models for evaluating pharmaceutical compounds
EP3352782B1 (en)	2015-09-25	2021-03-31	ImCyse SA	Improved methods and compounds for eliminating immune responses to therapeutic agents
CN105200010B (zh) *	2015-10-15	2019-02-12	首都医科大学附属北京佑安医院	艾滋病感染者hla-a2特异性ctl细胞的体外培养方法及其专用培养基
WO2017136837A1 (en)	2016-02-06	2017-08-10	President And Fellows Of Harvard College	Recapitulating the hematopoietic niche to reconstitute immunity
WO2017182528A1 (en)	2016-04-19	2017-10-26	Imcyse Sa	Novel immunogenic cd1d binding peptides
AU2017295704B2 (en)	2016-07-13	2023-07-13	President And Fellows Of Harvard College	Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
CN110418651A (zh)	2016-08-02	2019-11-05	哈佛学院院长等	用于调节免疫应答的生物材料
CN110612115A (zh) *	2017-05-19	2019-12-24	学校法人庆应义塾	针对脑神经疾病的肽疫苗和肽疫苗组合物
TW202023581A (zh)	2018-08-02	2020-07-01	日商腫瘤療法科學股份有限公司	來自cdca1的胜肽及含有此的疫苗
WO2020061129A1 (en)	2018-09-19	2020-03-26	President And Fellows Of Harvard College	Compositions and methods for labeling and modulation of cells in vitro and in vivo
JP2022514568A (ja)	2018-12-17	2022-02-14	プレジデントアンドフェローズオブハーバードカレッジ	免疫系のモジュレーションのための生物工学的スキャフォールドおよびその使用
JP2022549270A (ja)	2019-09-23	2022-11-24	プレジデントアンドフェローズオブハーバードカレッジ	バイオマテリアルベースの無抗原ワクチンおよびその使用
CN111363026B (zh) *	2020-03-31	2022-03-25	浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院）	一种增强抗原多肽亲和力和稳定性的方法
KR102711471B1 (ko) *	2020-08-14	2024-09-30	서울대학교산학협력단	B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5861301A (en) *	1992-02-20	1999-01-19	American Cayanamid Company	Recombinant kinase insert domain containing receptor and gene encoding same
US6222012B1 (en)	1992-08-31	2001-04-24	Ludwig Institute For Cancer Research	Isolated nonapeptides presented by HLA molecules, and uses thereof
CN1173991C (zh) *	1992-11-13	2004-11-03	马克斯普朗克科学促进协会	作为血管内皮生长因子受体的f1k-1
JP3734262B2 (ja)	1993-03-25	2006-01-11	メルクエンドカンパニーインコーポレーテッド	血管内皮細胞増殖因子阻害剤
EP0841945B1 (en) *	1995-08-03	2006-03-08	Rijksuniversiteit te Leiden	Cell derived antigen presenting vesicles
US5853719A (en)	1996-04-30	1998-12-29	Duke University	Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6100071A (en) *	1996-05-07	2000-08-08	Genentech, Inc.	Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6080728A (en) *	1996-07-16	2000-06-27	Mixson; A. James	Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
US5942428A (en) *	1996-08-21	1999-08-24	Sugen, Inc.	Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases
DE19638745C2 (de) *	1996-09-11	2001-05-10	Schering Ag	Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
US6348333B1 (en) *	1997-01-17	2002-02-19	Toa Gosei Co., Ltd.	VEGF-binding KDR polypeptide
JP4405597B2 (ja) *	1997-06-18	2010-01-27	メルクエンドカムパニーインコーポレーテッド	ヒト受容体型チロシンキナーゼｋｄｒ
FR2766205B1 (fr)	1997-07-16	2002-08-30	Inst Nat Sante Rech Med	Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
EP1055684A4 (en) *	1997-12-05	2002-12-04	Kyogo Itoh	TUMORANTIGENS IN THE FORM OF PEPTIDE DERIVATIVES
AU2299099A (en)	1998-02-04	1999-08-23	Kyowa Hakko Kogyo Co. Ltd.	Antibodies against human vegf receptor kdr
GB9804121D0 (en) *	1998-02-26	1998-04-22	Cancer Res Campaign Tech	Anti-angiogenic vaccines: materials and methods relating thereto
CA2328893A1 (en) *	1998-05-20	1999-11-25	Kyowa Hakko Kogyo Co., Ltd.	Vegf activity inhibitors
AU749544B2 (en)	1998-06-25	2002-06-27	Dainippon Sumitomo Pharma Co., Ltd.	Tumor antigen peptides originating in cyclophilin B
WO2001012809A2 (en) *	1999-08-13	2001-02-22	Crucell Holland B.V.	Heterodimeric vegf variants used for inhibiting angiogenesis
US7264810B2 (en) *	2001-01-19	2007-09-04	Cytos Biotechnology Ag	Molecular antigen array
JP2002267285A (ja)	2001-03-12	2002-09-18	Denso Corp	冷房冷蔵装置
JP4068371B2 (ja)	2001-06-13	2008-03-26	株式会社トプコン	手術用顕微鏡
JP3640084B2 (ja)	2001-11-30	2005-04-20	日本電気株式会社	測位機能を搭載した携帯電話端末
CU23178A1 (es)	2002-04-15	2006-09-22	Ct Ingenieria Genetica Biotech	INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
EP2267023B1 (en) *	2002-09-12	2015-02-11	Oncotherapy Science, Inc.	KDR peptides and vaccines comprising the same
SI1539157T1 (sl)	2002-09-18	2013-11-29	Trustees Of The University Of Pennsylvania	Rapamicin za uporabo pri inhibiciji ali preprečevanju horoidalne neovaskularizacije
EP2289532A1 (en)	2005-02-28	2011-03-02	Oncotherapy Science, Inc.	Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
ES2405763T3 (es)	2007-02-16	2013-06-03	Oncotherapy Science, Inc.	Vacunoterapia para la neovascularización coroidea
TWI436775B (zh)	2007-08-24	2014-05-11	Oncotherapy Science Inc	以抗原胜肽合併化療藥劑治療胰臟癌

2003
- 2003-09-12 EP EP10010175.7A patent/EP2267023B1/en not_active Expired - Lifetime
- 2003-09-12 EP EP10010176.5A patent/EP2270042B1/en not_active Expired - Lifetime
- 2003-09-12 DK DK08018875.8T patent/DK2014678T3/da active
- 2003-09-12 PT PT08018875T patent/PT2014678E/pt unknown
- 2003-09-12 CN CN2007101802067A patent/CN101139393B/zh not_active Expired - Fee Related
- 2003-09-12 JP JP2004571938A patent/JP3971769B2/ja not_active Expired - Lifetime
- 2003-09-12 EP EP10010173.2A patent/EP2261249B1/en not_active Expired - Lifetime
- 2003-09-12 PT PT03795432T patent/PT1548032E/pt unknown
- 2003-09-12 EP EP10010171A patent/EP2261247A3/en not_active Withdrawn
- 2003-09-12 AT AT08018875T patent/ATE531729T1/de active
- 2003-09-12 SI SI200332101T patent/SI2014678T1/sl unknown
- 2003-09-12 AT AT03795432T patent/ATE432291T1/de active
- 2003-09-12 WO PCT/JP2003/011722 patent/WO2004024766A1/ja not_active Ceased
- 2003-09-12 ES ES08018875T patent/ES2375299T3/es not_active Expired - Lifetime
- 2003-09-12 AU AU2003264419A patent/AU2003264419A1/en not_active Abandoned
- 2003-09-12 US US10/527,496 patent/US7514084B2/en not_active Expired - Fee Related
- 2003-09-12 SI SI200331649T patent/SI1548032T1/sl unknown
- 2003-09-12 DK DK10010175.7T patent/DK2267023T3/da active
- 2003-09-12 DK DK10010174.0T patent/DK2267022T3/da active
- 2003-09-12 DE DE60327786T patent/DE60327786D1/de not_active Expired - Lifetime
- 2003-09-12 ES ES03795432T patent/ES2327040T3/es not_active Expired - Lifetime
- 2003-09-12 EP EP03795432A patent/EP1548032B9/en not_active Expired - Lifetime
- 2003-09-12 EP EP08018897A patent/EP2014679B1/en not_active Expired - Lifetime
- 2003-09-12 CN CN2007101802052A patent/CN101139392B/zh not_active Expired - Fee Related
- 2003-09-12 CN CN201410214247.3A patent/CN103951745A/zh active Pending
- 2003-09-12 EP EP10010174.0A patent/EP2267022B1/en not_active Expired - Lifetime
- 2003-09-12 CN CN201210430723.6A patent/CN103073620B/zh not_active Expired - Fee Related
- 2003-09-12 DK DK10010173.2T patent/DK2261249T3/da active
- 2003-09-12 CN CNB038250810A patent/CN100352843C/zh not_active Expired - Lifetime
- 2003-09-12 DK DK10010169.0T patent/DK2267021T3/da active
- 2003-09-12 EP EP10010170.8A patent/EP2270041B1/en not_active Expired - Lifetime
- 2003-09-12 DK DK03795432T patent/DK1548032T3/da active
- 2003-09-12 EP EP10010172.4A patent/EP2261248B1/en not_active Expired - Lifetime
- 2003-09-12 EP EP08018875A patent/EP2014678B1/en not_active Expired - Lifetime
- 2003-09-12 EP EP10010169.0A patent/EP2267021B1/en not_active Expired - Lifetime
2007
- 2007-03-08 JP JP2007058127A patent/JP4185143B2/ja not_active Expired - Fee Related
- 2007-05-08 JP JP2007123850A patent/JP4185147B2/ja not_active Expired - Fee Related
2009
- 2009-01-16 US US12/355,616 patent/US7695720B2/en not_active Expired - Lifetime
- 2009-08-12 CY CY20091100856T patent/CY1109463T1/el unknown
2010
- 2010-02-23 US US12/711,159 patent/US8206719B2/en not_active Expired - Fee Related
2012
- 2012-01-19 CY CY20121100072T patent/CY1113379T1/el unknown
- 2012-06-12 US US13/494,933 patent/US8574586B2/en not_active Expired - Fee Related
- 2012-06-12 US US13/494,930 patent/US8574585B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN100352843C (zh)	2007-12-05
HK1151039A1 (en)	2012-01-20
JP2007191485A (ja)	2007-08-02
EP1548032A4 (en)	2006-03-01
CN103073620A (zh)	2013-05-01
EP2261248A3 (en)	2011-02-16
CN1694901A (zh)	2005-11-09
EP2261247A2 (en)	2010-12-15
EP2014678A2 (en)	2009-01-14
DE60327786D1 (de)	2009-07-09
ES2375299T3 (es)	2012-02-28
EP2261248A2 (en)	2010-12-15
EP1548032A1 (en)	2005-06-29
ATE432291T1 (de)	2009-06-15
EP1548032B1 (en)	2009-05-27
CN101139393A (zh)	2008-03-12
EP2261247A3 (en)	2011-02-16
JP4185143B2 (ja)	2008-11-26
CY1113379T1 (el)	2016-06-22
EP2261249B1 (en)	2015-02-11
US8574586B2 (en)	2013-11-05
US20100215676A1 (en)	2010-08-26
EP2267023A3 (en)	2011-02-16
HK1151036A1 (en)	2012-01-20
EP2270041B1 (en)	2015-02-25
EP2014679B1 (en)	2010-05-05
JP3971769B2 (ja)	2007-09-05
DK2261249T3 (da)	2015-02-16
PT2014678E (pt)	2012-01-05
HK1151038A1 (en)	2012-01-20
SI2014678T1 (sl)	2012-03-30
HK1124077A1 (en)	2009-07-03
WO2004024766A1 (ja)	2004-03-25
DK2267022T3 (da)	2015-02-23
CN103951745A (zh)	2014-07-30
EP1548032B9 (en)	2009-10-28
EP2270041A2 (en)	2011-01-05
EP2267021A2 (en)	2010-12-29
HK1151037A1 (en)	2012-01-20
EP2270041A3 (en)	2011-02-16
EP2267022A2 (en)	2010-12-29
DK2267021T3 (da)	2015-03-30
DK1548032T3 (da)	2009-08-17
EP2267021A3 (en)	2011-02-16
CN101139392B (zh)	2012-12-26
SI1548032T1 (sl)	2009-10-31
CN101139393B (zh)	2010-11-24
EP2267022B1 (en)	2015-02-11
EP2270042A3 (en)	2011-02-16
DK2267023T3 (da)	2015-02-23
EP2014679A1 (en)	2009-01-14
EP2267023B1 (en)	2015-02-11
CN103073620B (zh)	2014-12-10
US20130028923A1 (en)	2013-01-31
EP2267022A3 (en)	2011-02-16
US8574585B2 (en)	2013-11-05
EP2261248B1 (en)	2015-02-18
EP2270042A2 (en)	2011-01-05
HK1151032A1 (en)	2012-01-20
EP2014678A3 (en)	2009-03-25
US20090252752A1 (en)	2009-10-08
ATE531729T1 (de)	2011-11-15
JPWO2004024766A1 (ja)	2006-01-26
EP2267021B1 (en)	2015-02-18
ES2327040T3 (es)	2009-10-23
JP4185147B2 (ja)	2008-11-26
EP2267023A2 (en)	2010-12-29
US20120328636A1 (en)	2012-12-27
US7514084B2 (en)	2009-04-07
EP2261249A2 (en)	2010-12-15
PT1548032E (pt)	2009-08-13
EP2014678B1 (en)	2011-11-02
CY1109463T1 (el)	2014-08-13
EP2261249A3 (en)	2011-02-16
US8206719B2 (en)	2012-06-26
CN101139392A (zh)	2008-03-12
US20060216301A1 (en)	2006-09-28
EP2270042B1 (en)	2015-01-14
JP2007277251A (ja)	2007-10-25
HK1125659A1 (en)	2009-08-14
AU2003264419A1 (en)	2004-04-30
US7695720B2 (en)	2010-04-13

Publication	Publication Date	Title
DK1548032T3 (da)	2009-08-17	KDR-peptider og vacciner indeholdende disse
DK1005540T3 (da)	2004-10-18	IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
BR0211200A (pt)	2004-09-28	Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
MXPA02012743A (es)	2003-04-25	Moleculas tipo il-17 y usos de las mismas.
WO2006090810A3 (en)	2007-03-29	Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
DE50112802D1 (de)	2007-09-13	Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
GB0202556D0 (en)	2002-03-20	Novel Protein
DE60230456D1 (de)	2009-01-29	Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
CY1112867T1 (el)	2016-04-13	Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια
ATE495247T1 (de)	2011-01-15	Chromoprotein und fluoroproteine
WO2006116322A3 (en)	2008-01-17	Nicotinamide riboside kinase compositions and methods for using the same
DE69426121D1 (de)	2000-11-16	Gen grb3-3, variante und ihre verwendungen
DK1095143T3 (da)	2009-01-05	Inhibitor til diagnosticering og behandling af patienter med hæmofili A
EP4047009A3 (en)	2022-11-16	Wdrpuh epitope peptides and vaccines containing the same
DK2186898T3 (da)	2015-06-22	Blomstrings-induktion
DE10394174D2 (de)	2005-11-10	Peptide mit hohem Cysteingehalt
WO2007026171A3 (en)	2007-05-03	Vdcc gamma-8 ion channel
CY1114720T1 (el)	2016-10-05	Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια
SE9901115D0 (sv)	1999-03-25	Nucleotide sequences